GW3965 |
Agonist of NR1H2, NR1H3
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| NR1H2 |
|
|
| NR1H3 |
|
|
Agonist
100 nM - 1 uM
Selectivity
In Vitro Selectivity Assessment
Potency Assay Off-Target:
In a panel of nuclear receptors, GW3965 was only active against LXR and PXR. Panel included: PPARalp ...
Selectivity Assessment Description:
In a panel of nuclear receptors, GW3965 was only active against LXR and PXR. The panel included: PPA ...
Potency Cellular
In Vitro
NR1H2
Mode of Action: Agonist
Structure-Activity-Relationship data available? No
DOI Reference: 10.1021/jm0255116
NR1H3
Mode of Action: Agonist
Structure-Activity-Relationship data available? No
DOI Reference: 10.1021/jm0255116
In Vivo Validations
Mouse
Dose: 10 mg/kg
Route of delivery:
Oral
Plasma half life:
2 h
Organ of interest (O):
Plasma, small intestine, peripheral macrophages
Target engagement assay:
Indirect: In small intenstine and peripheral macrophages, GW3965 increased ABCA1 7-8 fold. In plasma, GW3965 increased HDL cholesterol 30%.
DOI Reference: 10.1021/jm0255116
Chemical Information
| Molecular Formula | C33H31ClF3NO3 |
| SMILEs | O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1 |
| InChI | InChI=1S/C33H31ClF3NO3/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40) |
| Molecular weight | 581.19 Da |
| AlogP | 8.0891 |
| HBond acceptors | 4 |
| HBond donors | 1 |
| Atoms | 72 |
References
Publications
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.